Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Repligen Corporation Common Stock — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $14.96 (market cap $7.03B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 69 Days and Repligen Corporation Common Stock for 0 Days on average.
| NCLH | RGEN | |
|---|---|---|
Market Cap | $7.03B | $11.14B |
Volume | 12,698,429 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $194.57 |
52-Week Low | $14.12 | $102.87 |
Typical Hold Time | 69 Days | 0 Days |
Enterprise Value | $21.85B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $15.32, down 0.2% on the day, with a neutral technical signal and bearish moving averages. The company reported Q2 2026 EPS of $0.48, beating expectations, and expects Q3 results to exceed guidance. Revenue grew to $9.83B in 2025, with a net income margin of 4.3%. Valuation ratios appear attractive with a P/E of 9.28 and P/S of 0.74. Recent news highlights pricing strategies to boost advance bookings and a $950M senior notes offering.
The outlook is mixed: strong earnings beats and analyst buy consensus (51.35%) support upside to the $20.86 price target, but high debt levels and yield pressure pose risks. Investors should weigh solid fundamentals against industry headwinds and financial leverage.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
